Alzheimer’s Disease and Acetylcholinesterase Inhibitor Agents: A Two-Year Longitudinal Study

Fuschillo, C.; Ascoli, E.; Franzese, Giuseppina; Campana, Fabio; Cello, Christophe; Galdi, M.; Pia, Silvestro La; Cetrangolo, C.

doi:10.1016/j.archger.2004.04.026

Cited by 6 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study [34] was only available as an abstract and therefore reported limited study details, which resulted in a score of 4 on the NOS scale. The remaining 9 studies [23,[26][27][28][29][30][31][32][33] were judged to be of good quality (range: 7-9).…”

Section: Resultsmentioning

confidence: 99%

“…However, only 5% of subjects (n = 19) were prescribed galantamine in this study. In the third study, results from 354 subjects evaluated at a single AEU between November 2000 and November 2002 were reported [27] . In the final study, 242 treatmentnaïve subjects referred to a single AEU were followed for 6 months [31] .…”

Section: Prospective Study Characteristicsmentioning

confidence: 99%

“…Two prospective studies reported the incidence of total GI AEs [31,32] , while the incidence of individual GI AEs was reported in 3 studies [27,31,34] ( table 5 ). Total GI AEs were reported at a similar incidence across the 3 treatment groups in 1 study [31] , but occurred in more galantamine-(24%) and rivastigmine-treated subjects (14%) compared with donepezil in a second study (6%) [32] .…”

Section: Gastrointestinal Aesmentioning

confidence: 99%

“…Four of the six prospective studies reported data from the CRONOS project, a national project initiated by the Italian government in October 2000 [26,27,31,32] . The project involved 503 Alzheimer evaluation units (AEUs) and aimed to standardise ChEI prescriptions and to assess their effects on defined outcomes (cognition, functional status, behaviour) in non-selected subjects with mild to moderate AD [35] .…”

Section: Prospective Study Characteristicsmentioning

confidence: 99%

“…The project involved 503 Alzheimer evaluation units (AEUs) and aimed to standardise ChEI prescriptions and to assess their effects on defined outcomes (cognition, functional status, behaviour) in non-selected subjects with mild to moderate AD [35] . No restrictions on which ChEI was prescribed were applied in 3 of the 4 studies [26,27,31,32] , although galantamine only became available for treatment from April 2001 onwards. However, in the study by Aguglia et al [31] , treatment was assigned in a pseudo-randomised fashion based on arrival at the AEU following the availability of galantamine.…”

Section: Prospective Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer’s Disease: Systematic Review of the ‘Real-World’ Evidence

Lockhart

Mitchell

Kelly

2009

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background/Aims: The purpose of this systematic review was to compare the safety and tolerability of the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine for treating mild to moderate Alzheimer’s disease (AD) patients in routine clinical practice. Methods: Electronic databases (Cochrane Library, Medline, EMBASE; accessed October 2008) and manual bibliographic searches were conducted to identify head-to-head non-randomised studies examining ChEIs for the treatment of AD. Data were extracted by 2 independent reviewers. Results: Twelve head-to-head studies comparing ChEIs met the pre-specified inclusion criteria; 6 retrospective analyses and 6 prospective cohort studies. Donepezil was the most widely studied treatment and galantamine the least widely prescribed therapy. Fewer donepezil-treated subjects withdrew due to adverse events (AEs) compared with rivastigmine and galantamine-treated subjects. The incidence of gastrointestinal (GI) AEs was lower following treatment with donepezil compared with rivastigmine and galantamine. Non-GI (CNS and cardiovascular) AEs occurred at a low frequency, and had a similar incidence in subjects treated with the different ChEIs. Conclusions: Subjects with mild to moderate AD treated in routine clinical practice with donepezil were more adherent to pharmacotherapy, and had a lower risk of GI AEs compared with rivastigmine or galantamine. This finding accords with results reported in the randomised clinical trial literature.

show abstract